this post is fantastic saw palmetto dose for female hair loss ALX-0061 is Ablynx’s anti-IL-6R Nanobody that successfully completed a Phase IIa study reporting efficacy and safety data in patients with moderately to severely active rheumatoid arthritis on a stable background of methotrexate. Ablynx will be responsible for completing Phase II clinical development in both RA and systemic lupus erythematosus. Upon the achievement of pre-defined success criteria, AbbVie will exercise its right to in-license ALX-0061 and be responsible for subsequent Phase III clinical development and commercialization.